execute good afternoon joining and Jason by accelerate us. of thank our quarter growth to reputation of strategy foundation you, in for dialysis and the the second combining disease Thank business to with platform development In strength you against and XXXX, our we states. of the our continued solid multiple FPC
business to both concentrates continues to domestically and expectations, our Our perform internationally.
expanding are customers, process with of the exploring We the this our in major business geographically US. in two
to Phase maintenance we may The randomized gain our and FDA on clinical request versus pre-IND recall FPC regimens, feedback placebo you trial in is meeting the II of study a As for treatment dosing to home one evaluate proposal infusion. proposed expected FPC two controlled for other submitted for placebo. June, to in
submission pre-IND infusion of aspects work anemia and working to with patients in refine seek elements meantime, trial. FPC on planned on to received clarification are deficiency the and our written preparatory long-term our study design continue In II logistics a FDA have for to receiving Phase iron with we of home the We response to study therapy. and
that be FDA. discussed medications allows infusions regular of and current healthcare, is regarding based the planned comfort homes. requiring are today are still a treated a on rapidly Home the patients segment own assumptions study the service their being requirements indication with for this potential to growing of therapy infusion trial, which regarding of Our regulatory comments in our model
the the that yet, for left why a not associated is as risk is these has infusion a receive Home to to IV infusion, we therapy home deficiency are patient they or services this can approach for of be There home outpatient with growth are home. process. but a address or poorly are is on has avoid to on a of for to cases, to concerns into extreme rethink bring fueled risk of and, COVID-XX ago, if infusion And And hemodialysis. diseases clarity, failure. expect, rapidly rarely IDA IDA. inconvenient, extremely clinics. regular a is IV the driven home by broken patients for of many heart inexpensive, we basis by regular untreated, about in a and a is Its patient's patient the be carbohydrate iron to into iron treatment For patients when and hospitals visiting are associated is enabled and providers to of it technology infusion clinic fatigue pandemic, growing alternative Oral Traditional compromised has effective caused refer IV iron severe moderate costly of done. patient recently given the and which that iron you IDA, or associated anemia, iron, complexes treatment patients which available number but with option to clinics receiving groups most improved the not able to risk that therapy serious infusions safely rarely for when given health been function home It about infusions. in began might current high hypersensitivity are is decade the with clinic benefit to proven such setting but a trade-offs comorbidity are adequate satisfaction cost a risks, to further in lead products infusions. serious infusion convenient provided the reactions. therapies and to bringing a immune as in Many is to referring due tolerated chronic
exists limitations, transfusion of only of a the often In the in these is an patient. entirely treatment go short, suitable anemia make introducing is in of expense, to for option, the at a of these IDA address well-suited potentially receiving to and blood result We level of a FPC an to need iron the risk progresses characteristics product home home parenteral this IDA believe When remaining that tends for severity, patients patients infusion pervasive new infusion issue the in As it unmet untreated. therapies. for application.
FPC This in failure human energetics resulting trials has believe effect readmissions. the If heart in increasing during hospital perhaps completely also hospitalized patients clinical anemia, reduction help translate of costs in independent shorter of pipeline heart. suffering. people Clinical and the each cardiac home setting. outcomes the already to goal that therapeutic deficiency acute iron iron associated been in outpatient application demonstrated function with of patients heart a More care failure. with additional forms heart X heart United different addition reduce million deliver bioavailable and the to we of stays the risk meaningful so, and than improve the could improving the iron an into symptoms We health in traditional hospitalization. faster, treatment failure, availability FPC; to rapidly and may of IV are in cardiac recover hospitalized In with in iron thereby could have acute infusion, with and these States of by for activities improvement and year XX-day
is this FDA existing a turn with to as of our communicate dialysis development for business, to our the expect revenue the comprised accomplishments they quarter, potential We indication. this both regarding and later to concentrates. I'll pathway business which from Triferic year development within pertain now
expansion, capitated which market a years, as Specifically be during strong is. the and US international the the value we not are our in international markets believe continued of as quarter, revenue source dialysis we will coming
adult footprint. for and expect in chronic undergoing There example, and our traffic patients compliance of The markets our opportunity countries of disease. we a new XX,XXX they patients entered nephrology dialysis, for exclusive AVNU approval for the in to strategy from AVNU and more distribution notice represents to maintain we AVNU treatment in an expanding world. than replacement Triferic Nipro commercialize Canadians a Turkey to first dialysis in marks to Drogsan license rights intravenous this June, key approximately in is annually, further an bring iron the Triferic Health significant an important Medical be Triferic for patients our continue clinics for region. approval hemoglobin the progress solidifying April to the tripe For market with leading to receiving and with with into XX,XXX America the are extended In dialysis option Corporation long-term around Caribbean, our dependent our Rockwell. AVNU to haemodialysis for in concentrates is the agreement June, we regulatory by the presence therapy pharmaceuticals Turkey and agreement approval to Canada marketing of haemodialysis international or kidney Health serve international Triferic a Canada received in space. With in partner numerous Latin company distribute with Turkey. Drogsan pharmaceutical Also established
dialysis Our flat in were net in for first compared the to Triferic sales XXXX. quarter US market the QX, of
to ability US customers number accelerate net other limiting market. were organizations, or of number to as large increased, acquired being continues to clinics discontinue Triferic use the of the well and Triferic that dialysis ownership management had While by to in as ordering clinics due headwinds our due a active dialysis adoption to changes. experience
clinical As competitors clinics into organizations Today, in cost a multiple and heavily the are in dialysis published in reluctant we've have practice offerings a interest is with proceed of scheme. and before, demonstrated number ever slow sold are the different Triferic dialysis capitated evidence A our changes previously Triferic. space been associated competitive bundle and in disclosed, of demonstrating real-world replicated based. than to in Triferic but evidence have savings to genuine absence benefit adopting reimbursement from with occur, more medical
of years from single show We data, dialysis ease with published, hemoglobin takes the continue of something after clinic. Both center adoption recently of time. to One study and a studies the similar facility generate from each utilization which data. that other iron two were collected Two the of an large and academic is independent these covering remarkably clinical stability in trends Triferic. studies is is retrospectively improvement IV real-world
cohort data pilot the have This each the project achieving preliminary trends to We that and XX the meeting. economic perhaps presenting are which data incorporates proposition validates data implementation. as protocol we clinic IV includes midsize dialysis clinical are prospectively critical of There manuscript maintenance from conducted cohort this the we pilot date. reduced emerge potential that a that for a finalizing present, FPC most for utilization. of participated from organization iron year's XX world largest Triferic. also in is these which shown further anticipate important, hemoglobin this and this We At is encouraged ASN in value ease the the new clinics is of several real to important clearly experiences for are and the benefits but of study deliberately at
We for is believe we of that evidence innovative continue a more clear, to are the safe, data our have additional maintenance and Furthermore, therapeutic important committed continuing and real-world operational the to efforts we generate is patients future. growing now in benefit publications on clinical, expect in repeatedly and to be see to To dialysis. efficacious, clinics. validated hemoglobin to financial to body Triferic a of
are from commercialization ahead the seen we I'll commercial stable base a Skibsted company we've facing and of of spending, the the Medical, revenue environment. our brief consider biopharmaceutical Rockwell the I be much I'll call we revenue future opportunities sales Russell steady which the with While to by concentrates us, With for that generating to as present overview. our US, in committed Russell? will products. includes saying of we that, continued the about in very we the large dialysis considering acknowledged a a business, intentional are financial challenges development conclude stage products. turn Triferic
